Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H34N8O5S |
Molecular Weight | 582.674 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN1CCN(CC1)S(=O)(=O)C2=CN=C(OCCOC)C(=C2)C3=NC4=C(CC)N(CC5=CC=CC=N5)N=C4C(=O)N3
InChI
InChIKey=QDPNAMRLQRQPMR-UHFFFAOYSA-N
InChI=1S/C27H34N8O5S/c1-4-22-23-24(32-35(22)18-19-8-6-7-9-28-19)26(36)31-25(30-23)21-16-20(17-29-27(21)40-15-14-39-3)41(37,38)34-12-10-33(5-2)11-13-34/h6-9,16-17H,4-5,10-15,18H2,1-3H3,(H,30,31,36)
Molecular Formula | C27H34N8O5S |
Molecular Weight | 582.674 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:47:15 GMT 2023
by
admin
on
Sat Dec 16 11:47:15 GMT 2023
|
Record UNII |
D36Q3E2UUJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
135456180
Created by
admin on Sat Dec 16 11:47:15 GMT 2023 , Edited by admin on Sat Dec 16 11:47:15 GMT 2023
|
PRIMARY | |||
|
247580-98-9
Created by
admin on Sat Dec 16 11:47:15 GMT 2023 , Edited by admin on Sat Dec 16 11:47:15 GMT 2023
|
PRIMARY | |||
|
D36Q3E2UUJ
Created by
admin on Sat Dec 16 11:47:15 GMT 2023 , Edited by admin on Sat Dec 16 11:47:15 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Structure of UK-357,903 and IC50 values for inhibition of phosphodiesterase (PDE) enzymes.
Enzyme: PDE5, PDE6a, PDE1-3 and 7-11; Geometric mean IC50 (nM) (nX3) 95% CI;
PDE5 1.3 (1.11.6); PDE6a 714 (575887); PDE1-3 and 7-11 410,000
|
||
|
ACTIVE MOIETY |
Mechanism of Action: Type 5 cyclic nucleotide phosphodiesterase inhibitor; Highest Development Phase: Discontinued for Erectile dysfunction; Most Recent Event: 05 Sep 2006 Discontinued - Phase-II for Erectile dysfunction in Europe (unspecified route)
|
||
|
ACTIVE MOIETY |
Nitric oxide is the main inhibitory neurotransmitter in the internal anal sphincter. UK 357,903 (an inhibitor of type-5 phosphodiesterase (PDE)) prevents hydrolysis of cyclic guanosine monophosphate, enhancing the effect of nitric oxide.
|
||
|
ACTIVE MOIETY |
The regional hemodynamic responses to continuous 4-day infusion of UK-357,903 (266 microg kg(-1) h(-1)) alone and in combination with a low dose of enalapril (10 microg kg(-1) h(-1)) were measured in conscious spontaneously hypertensive rats to test the hypothesis that the renin-angiotensin system may influence the cardiovascular consequences of inhibition of phosphodiesterase 5 (PDE5) by UK-357,903 or vice versa. UK-357,903 alone caused a fall in mean blood pressure (-12.1 mm Hg) associated with vasodilatation in the mesenteric and hindquarters vascular beds.
|